Jild 3 № 2 (2026): Aprel - Iyun
97-110
2026-09-02
Ochiq kirish

Aterogenezda CD36 skavenjer-retseptorining o‘rni: molekulyar mexanizmlar va terapevtik istiqbollar

Dilnora Yusupalieva
R.B.Aliyeva
Sh.Musabayeva
U.I.Nizamov
Sh.S.Axmedova
A.B.Shek
https://doi.org/10.70626/cardiouz-2026-3-00092

Qabul qilingan: 2026-09-07

Nashr etilgan: 2026-09-02

PDF (ruscha)
Crossmark Crossmark

Annotatsiya

B sinf 2-tur skavenjer-retseptori (CD36) — uzun zanjirli yog‘ kislotalari tashuvchisi, oksidlangan past zichlikdagi lipoproteinlar retseptori, patternni taniydigan retseptor va hujayra ichidagi signal platformasi vazifalarini birlashtirgan ko‘p ligandli transmembran glikoproteindir. Sharhda CD36 tuzilishi to‘g‘risidagi zamonaviy ma’lumotlar, jumladan ektodomenning rentgen tuzilmaviy tahlili, hamda uning aterogenezdagi ishtiroki mexanizmlari tizimlashtirilgan: modifikatsiyalangan lipoproteinlarni qamrab olish, ko‘pikli hujayralar shakllanishi, CD36–TLR4/TLR6–NF-κB va CD36–TLR2 o‘qlarining hamda NLRP3 inflammasomasining faollashuvi, mitoxondrial oksidlanish stressi, efferotsitoz buzilishi va nekrotik yadro shakllanishi. CD36 ning yurak ishemik kasalligi bilan bog‘liqligi tanqidiy baholangan: global va hujayraga xos nokaut modellari, shu jumladan retseptorning makrofaglar va endoteliyda induksiyalanadigan deletsiyasi, retseptorning inson blyashkalari va monotsitlaridagi ekspressiyasi, eriydigan CD36 bo‘yicha qarama-qarshi ma’lumotlar, genetik assotsiativ tadqiqotlar va CD36 irsiy tanqisligining paradoksal fenotipi. Selektiv peptid va azapeptid ligandlar, antisens oligonukleotidlar, posttranslyatsion modifikatsiyalar va membrana trafigiga ta’sir, manzilli nanotizimlar muhokama qilinadi. CD36 aterosklerozda qoldiq yallig‘lanish xavfi nishoni roliga eng asoslangan nomzodlardan biri bo‘lib qolmoqda — retseptorni tizimli bostirish emas, balki hujayraga selektiv modulyatsiya qilish sharti bilan.

Kalit so‘zlar

Adabiyotlar ro'yxati

  1. Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023. J Am Coll Cardiol. 2025;86(22):2167-2243. https://doi.org/10.1016/j.jacc.2025.08.015

  2. GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406(10513):1811-1872. https://doi.org/10.1016/S0140-6736(25)01917-8

  3. Mensah GA, Fuster V, Murray CJL, Roth GA. Global burden of cardiovascular diseases and risks, 1990-2022. J Am Coll Cardiol. 2023;82(25):2350-2473. https://doi.org/10.1016/j.jacc.2023.11.007

  4. Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524-533. https://doi.org/10.1038/s41586-021-03392-8

  5. Bjo¨rkegren JLM, Lusis AJ. Atherosclerosis: recent developments. Cell. 2022;185(10):1630-1645. https://doi.org/10.1016/j.cell.2022.04.004

  6. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. Eur Heart J. 2017;38(32):2459-2472. https://doi.org/10.1093/eurheartj/ehx144

  7. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131. https://doi.org/10.1056/NEJMoa1707914

  8. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838-1847. https://doi.org/10.1056/NEJMoa2021372

  9. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993;268(16):11811-11816.

  10. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009;2(72):re3. https://doi.org/10.1126/scisignal.272re3

  11. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001;108(6):785-791. https://doi.org/ 10.1172/JCI14006

  12. Shu H, Peng Y, Hang W, Nie J, Zhou N, Wang DW. The role of CD36 in cardiovascular disease. Cardiovasc Res. 2022;118(1):115-129. https://doi.org/10.1093/cvr/cvaa319

  13. Tian K, Xu Y, Sahebkar A, Xu S. CD36 in atherosclerosis: pathophysiological mechanisms and therapeutic implications. Curr Atheroscler Rep. 2020;22(10):59. https://doi.org/10.1007/s11883-020-00870-8

  14. Hsieh FL, Turner L, Bolla JR, Robinson CV, Lavstsen T, Higgins MK. The structural basis for CD36 binding by the malaria parasite. Nat Commun. 2016;7:12837. https://doi.org/10.1038/ncomms12837

  15. Glatz JFC, Heather LC, Luiken JJFP. CD36 as a gatekeeper of myocardial lipid metabolism and therapeutic target for metabolic disease. Physiol Rev. 2024;104(2):727-764. https://doi.org/10.1152/physrev.00011.20 23

  16. Podrez EA, Poliakov E, Shen Z, et al. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem. 2002;277(41):38503-38516. https://doi.org/10.1074/jbc.M203318200

  17. Kunjathoor VV, Febbraio M, Podrez EA, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. 2002;277(51):49982-49988. https://doi.org/10.1074/jbc.M209649200

  18. Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, Silverstein RL. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab. 2006;4(3):211-221. https://doi.org/10.1016/j.cmet.2006.06.007

  19. Park YM, Febbraio M, Silverstein RL. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima. J Clin Invest. 2009;119(1):136-145. https://doi.org/10.1172/JCI35535

  20. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010;11(2):155-161. https://doi.org/10.1038/ni.1836

  21. Sheedy FJ, Grebe A, Rayner KJ, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol. 2013;14(8):812-820. https://doi.org/10.1038/ni.2639

  22. Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 2010;12(5):467-482. https://doi.org/10.1016/j.cmet.2010.09.010

  23. Chen Y, Yang M, Huang W, et al. Mitochondrial metabolic reprogramming by CD36 signaling drives macrophage inflammatory responses. Circ Res. 2019;125(12):1087-1102. https://doi.org/10.1161/ CIRCRESAHA.119.315833

  24. Podrez EA, Byzova TV, Febbraio M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007;13(9):1086-1095. https://doi.org/10.1038/nm1626

  25. Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105(8):1049-1056. https://doi.org/10.1172/JCI9259

  26. Febbraio M, Guy E, Silverstein RL. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24(12):2333-2338. https://doi.org/10.1161/01.ATV.0000148007.06370.68

  27. Moore KJ, Kunjathoor VV, Koehn SL, et al. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest. 2005;115(8):2192-2201. https://doi.org/10.1172/JCI24061

  28. Manning -Tobin JJ, Moore KJ, Seimon TA, et al. Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler Thromb Vasc Biol. 2009;29(1):19-26. https://doi.org/10.1161/ATVBAHA.108.176644

  29. Gissler MC, Mwinyella T, Horstmann H, et al. Macrophage expressed CD36 drives plaque destabilisation in atherogenesis [abstract]. Atherosclerosis. 2024. https://doi.org/10.1016/j.atherosclerosis.2024.118344

  30. Rekhi UR, Omar M, Alexiou M, Delyea C, Immaraj L, Elahi S, Febbraio M. Endothelial cell CD36 reduces atherosclerosis and controls systemic metabolism. Front Cardiovasc Med. 2021;8:768481. https://doi.org/10.3389/fcvm.2021.768481

  31. Nakagawa-Toyama Y, Yamashita S, Miyagawa J, et al. Localization of CD36 and scavenger receptor class A in human coronary arteries: a possible difference in the contribution of both receptors to plaque formation. Atherosclerosis. 2001;156(2):297-305. https://doi.org/10.1016/S0021-9150(00)00659-4

  32. Handberg A, Skjelland M, Michelsen AE, et al. Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability. Stroke. 2008;39(11):3092-3095. https://doi.org/10.1161/STROKEAHA.108.517128

  33. Handberg A, Højlund K, Gastaldelli A, et al. Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. J Intern Med. 2012;271(3):294-304. https://doi.org/10.1111/j.1365-2796.2011.02442.x

  34. Rac´ M, Krzystolik A, Rac´ M, et al. Is plasma-soluble CD36 associated with density of atheromatous plaque and ankle-brachial index in early-onset coronary artery disease patients? Kardiol Pol. 2016;74(6):570-575. https://doi.org/10.5603/KP.a2015.0234

  35. Wang Y, Zhu J, Handberg A, et al. Association between plasma CD36 levels and incident risk of coronary heart disease among Danish men and women. Atherosclerosis. 2018;277:163-168. https://doi.org/10.1016/j.atherosclerosis.2018.08.045

  36. Luo Z, Lv L. Impacts of CD36 variants on plasma lipid levels and the risk of early-onset coronary artery disease: a systematic review and meta-analysis. Cardiovasc Ther. 2025;2025:8098173. https://doi.org/10.1155/cdr/8098173

  37. Momeni-Moghaddam MA, Asadikaram G, Akbari H, et al. CD36 gene polymorphism rs1761667 (G>A) is associated with hypertension and coronary artery disease in an Iranian population. BMC Cardiovasc Disord. 2019;19(1):140. https://doi.org/10.1186/s12872-019-1111-6

  38. Miyaoka K, Kuwasako T, Hirano K, Nozaki S, Yamashita S, Matsuzawa Y. CD36 deficiency associated with insulin resistance. Lancet. 2001;357(9269):686-687. https://doi.org/10.1016/S0140-6736(00)04138-6

  39. Yuasa-Kawase M, Masuda D, Yamashita T, et al. Patients with CD36 deficiency are associated with enhanced atherosclerotic cardiovascular diseases. J Atheroscler Thromb. 2012;19(3):263-275. https://doi.org/10.5551/jat.10603

  40. Kuda O, Pietka TA, Demianova Z, et al. Sulfo-N-succinimidyl oleate (SSO) inhibits fatty acid uptake and signaling for intracellular calcium via binding CD36 lysine 164: SSO also inhibits oxidized low density lipoprotein uptake by macrophages. J Biol Chem. 2013;288(22):15547-15555. https://doi.org/10.1074/jbc.M113.473298

  41. Wen SY, Zhi X, Liu HX, Wang X, Chen YY, Wang L. Is the suppression of CD36 a promising way for atherosclerosis therapy? Biochem Pharmacol. 2024;219:115965. https://doi.org/10.1016/j.bcp.2023.115 965

  42. Marleau S, Harb D, Bujold K, et al. EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J. 2005;19(13):1869-1871. https://doi.org/10.1096/fj.04-3253fje

  43. Harb D, Bujold K, Febbraio M, Sirois MG, Ong H, Marleau S. The role of the scavenger receptor CD36 in regulating mononuclear phagocyte trafficking to atherosclerotic lesions and vascular inflammation. Cardiovasc Res. 2009;83(1):42-51. https://doi.org/10.1093/cvr/cvp081

  44. Bujold K, Rhainds D, Jossart C, Febbraio M, Marleau S, Ong H. CD36-mediated cholesterol efflux is associated with PPARγ activation via a MAPK-dependent COX-2 pathway in macrophages. Cardiovasc Res. 2009;83(3):457-464. https://doi.org/10.1093/cvr/cvp118

  45. Fre´geau G, Sarduy R, Elimam H, et al. Atheroprotective and atheroregressive potential of azapeptide derivatives of GHRP-6 as selective CD36 ligands in apolipoprotein E-deficient mice. Atherosclerosis. 2020;307:52-62. https://doi.org/10.1016/j.atherosclerosis.2020.06.010

  46. Gauvin J, Fre´geau G, Elimam H, et al. A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice. Front Pharmacol. 2023;14:1204905. https://doi.org/10.3389/fphar.2023.1204905

Mualliflar haqida

Dilnora Yusupalieva
dbyusupalieva@gmail.com
a:1:{s:2:"en";s:76:"Republican Specialized Scientific and Practical Medical Center of Cardiology";}, Respublika ixtisoslashtirilgan kardiologiya ilmiy amaliy markazi
R.B.Aliyeva
ranoalieva35@gmail.com
Sh.Musabayeva
shmusabaeva@icloud.com
U.I.Nizamov
ulugbek1987nizamov@gmail.com
Sh.S.Axmedova
axmedovashoxista675@gmail.com
A.B.Shek
shek-999@mail.ru

Litsenziya

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Qanday iqtibos keltirish kerak

Aterogenezda CD36 skavenjer-retseptorining o‘rni: molekulyar mexanizmlar va terapevtik istiqbollar (D. Yusupalieva, R. Aliyeva, S. Musabayeva, U. Nizamov, S. Axmedova, & A. Shek, Trans.). (2026). O’ZBEKISTON KARDIOLOGIYASI, 3(2), 97-110. https://doi.org/10.70626/cardiouz-2026-3-00092
Crossref
Scopus
Google Scholar
Europe PMC

Ushbu muallif(lar)ning eng koʻp oʻqilgan maqolalari

O'xshash maqolalar

Siz ham ushbu maqola uchun {$ advancedSearchLink} olishingiz mumkin.

ISSN 3060-4850 (Print)